Contribute Try STAT+ Today

WASHINGTON The pharmaceutical industry made it clear to the Food and Drug Administration that it wants the regulatory flexibilities the agency has embraced during the Covid-19 pandemic to be made permanent — and it’s ready to push to make sure it happens. 

“There is a pressing need for FDA and industry to identify actions taken during the Covid-19 pandemic and evaluate their effectiveness and applicability to innovative drug development beyond the public health emergency,” said Lucy Vereshchagina, vice president of science and regulatory affairs at PhRMA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.